ClinicalTrials.gg
CompletedNCT05528120Updated Nov 30, 2022

Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

A Phase 1 interventional study of VC004 Capsules and VC004 Capsules in Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate pharmacokinetics of a single oral dose of VC004 capsules under fasting and fed conditions in healthy subjects.

02

Conditions studied

  • Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

Keywords

  • healthy subjects
03

In context

Lead sponsor

Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 35 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written before study, and fully understand the study content, process and possible adverse reactions;
  2. Able to complete the study in compliance with the protocol;
  3. Subject (including partner) is willing to voluntarily take effective measures from screening through 6 months after the last dose of study drug (see Appendix 5 for details);
  4. Male and female subjects between the ages of 18 and 45 years, inclusive;
  5. At least 50.0kg for male subjects, 45.0kg for female subjects, with a (BMI= Weight/Height2) between 19.0-26.0 kg/m2, inclusive;

Exclusion criteria

Exclusion Criteria:

  1. More than 5 cigarettes per day on average within 3 months prior to screening;
  2. History of sensitivity to drugs similar to the study drug;allergic constitution (e.g. allergy to two or more kinds of drugs and food );
  3. History of drug and/or alcohol abuse (alcoholism defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or or have used drugs within the past five years;
  4. Donation or loss of a significant volume of blood (> 450 mL) within 3 months prior to screening;
  5. History of difficulties in swallowing or any history of gastrointestinal, liver, kidney disease (whether cured or not) or surgery that affects drug absorption or excretion within 6 months prior to screening;
  6. Those who Have taken strong inhibitors and / or inducers of liver metabolic enzymes (CYP1A2, 2A6, 2b6, 2c8, 2c19, 3A4 and 3A5) within 28 days before the first administration :strong inhibitors of liver metabolic enzymes such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, oleandomycin etc., strong inducers of liver metabolic enzymes such as rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc; Those who Have taken inhibitors and inducers of P-gp, MRPs, BCRP, OATP and other transporters and transporters within 28 days before the first administration; See Appendix 6 for details;
  7. Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;
  8. Taking foods that affect metabolism, such as grapefruit or drinks containing grapefruit within 2 weeks before the first drug administration, or taking high-intensity physical exercises (such as strength training, aerobic training and football playing) within 7 days before the first drug administration, or any other factors that affect drug absorption, distribution, metabolism and excretion;
  9. Recent major changes in diet or exercise habits within 7 days before the first medication;
  10. Participated in other clinical trials within 3 months before screening (if the subject withdraws from the study before treatment, i.e. has not been randomized or received treatment, he or she can be enrolled in the study);
  11. Those who cannot tolerate high-fat meals or have special requirements for diet and cannot accept unified diet;
  12. A vital signs abnormality during screening (body temperature (axillary temperature) \< 36.0 ℃ or > 37.0 ℃; Pulse \< 60bpm or > 100bpm; Systolic blood pressure \<90mmhg or ≥ 140mmHg, diastolic blood pressure \<60mmhg or ≥ 90mmHg);
  13. A clinically significant 12-lead abnormality;
  14. Positive test results of blood pregnancy or is lactating for female subjects;
  15. Any clinically significant abnormalities/findings in laboratory tests, or any clinically significant disease including but not limited to gastrointestinal, renal, hepatic, neurological system, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases;
  16. Positive test results for viral hepatitis (including and C), antibody or syphilis antibody during screening;
  17. Acute illness or concomitant medication from screening to the first dosing of study medication;
  18. Consumption of chocolate or any food or beverages containing caffeine or (rich containing) xanthine within 24 h prior to receiving the first dosing of study medication;
  19. Consumption of any product containing alcohol within 24 h prior to receiving the first dosing of study medication, or positive results from a screen for alcohol;
  20. Positive results from a screen for urine drug test;
  21. Cannot tolerate venipuncture and have a history of needle and blood sickness;
  22. Subjects were vaccinated within 4 weeks prior to screening, or planned to be vaccinated during the trial;
  23. Any condition which in the opinion of Investigator is not suitable for subjects to participate in the study or who are not suitable to participate according to the epidemic prevention and control requirements of the research center.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    KG

    Drug: VC004 Capsules

  • Experimental
    GK

    Drug: VC004 Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day1-Day8

  2. Peak time(Tmax)

    Time frame: Day1-Day8

  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)

    Time frame: Day1-Day8

07

Study locations

1 site
  • Zhongda Hospital,Affiliated to Southeast University
    Nanjing, Jiangsu 210009, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Oct 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2022
First posted
Sep 6, 2022
StartActual
Oct 20, 2022
Primary completionActual
Oct 28, 2022
CompletionActual
Nov 23, 2022
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05528120
Responsible party
Sponsor
First posted
Sep 6, 2022
Start date
Oct 20, 2022
Primary completion
Oct 28, 2022
Completion
Nov 23, 2022
Last update
Nov 30, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eratrectinib

Start the discussion